In the absence of IP-MS Aβ measures, GFAP is the best predictor of amyloidosis at the preclinical stage of AD and, in combination with p-tau181, best predicts amyloidosis at the symptomatic phase of the disease. This evidence concerns the gene GFAP and Alzheimer disease.